SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Madam C. J. Walker — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSarah Walker
Date of birth1867-12-23
IdentifiersMRN HR-ET019-SYN-TD; SSN (made up) 000-19-7062
Document date1917-04-27
AuthorHarriet Okonjo-Bell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Eleven-week review: home readings on maximum losartan, urine albumin, kidney function after a recent gastroenteritis, lipids on atorvastatin. [S]

History of Present Illness

Madam Walker returns two weeks after her sick visit for gastroenteritis. The vomiting and diarrhea settled within two days, and she restarted losartan and empagliflozin once she had eaten normally for a day. The potassium and creatinine check due two to four weeks after the losartan increase was not done: she was on a three-week convention tour and her office had booked no laboratory day. The panel planned for the week after the sick visit was also missed when she left on another trip. Her home readings on losartan 100 mg average 134/84. She has had no dizziness, cough, genital itching or muscle aches. She is asking for sauces on the side and no added salt at banquets. [S]

ElementDetail
Home blood pressureAverage 134/84 on losartan 100 mg
Missed checksPanel after the losartan increase, and the panel a week after the gastroenteritis
GastroenteritisResolved; losartan and empagliflozin restarted after a day of normal eating
Side effectsNone

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo dizziness; weight back up by 0.8 kg since the illness
GastrointestinalNegativeBowels normal
CardiovascularNegativeNo ankle swelling
GenitourinaryNegativeNo burning or genital itching
MusculoskeletalNegativeNo muscle aches

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Losartan 50 mg oral tablet, one tablet each morningOne tablet each morning, at the same home time when travelingOral route1917-02-23 to 1917-03-09completedS
Losartan 100 mg oral tablet, one tablet each morningOne tablet each morningOral route1917-03-09activeS
Empagliflozin 10 mg oral tablet, one tablet each morning; stop on days of vomiting, diarrhea or not eating, and before surgeryOne tablet each morning, with sick-day rulesOral route1917-02-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1917-02-23activeS
Ondansetron 4 mg orally disintegrating tablet, one tablet on the tongue every 8 hours as needed for nausea, for up to two daysEvery 8 hours as needed for nausea, up to two daysOral route1917-04-13 to 1917-04-15completedS
Amlodipine 5 mg oral tablet, one tablet dailyOne tablet dailyOral route1917-04-27activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1917-04-27Body height163cmS
1917-04-27Body weight77.2kgS
1917-04-27Body mass index (BMI) [Ratio]29.1kg/m2S
1917-04-27Systolic blood pressure136mm[Hg]S
1917-04-27Diastolic blood pressure86mm[Hg]S
1917-04-27Heart rate76/minS
1917-04-27Respiratory rate16/minS
1917-04-27Body temperature36.6CelS
1917-04-27Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1917-04-27Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1917-04-27Potassium [Moles/volume] in Serum or Plasma4.7mmol/L3.5-5.1 mmol/LNormalS
1917-04-27Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
1917-04-27Creatinine [Mass/volume] in Serum or Plasma1.31mg/dL0.59-1.04 mg/dLHighS
1917-04-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1912)/1.73 sq M50mL/min/{1.73_m2}60 or higher (G1 to G2) unless other kidney damage; 45 to 59 is G3aLowS
1917-04-27Albumin/Creatinine [Mass Ratio] in Urine176mg/gBelow 30 mg/g normal (A1); 30 to 300 moderately increased (A2); above 300 severely increased (A3)HighS
1917-04-27Cholesterol [Mass/volume] in Serum or Plasma172mg/dL<=199 mg/dLNormalS
1917-04-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation98mg/dLBelow 130 mg/dL; lower on treatment by at least 30%NormalS
1917-04-27Cholesterol in HDL [Mass/volume] in Serum or Plasma48mg/dL>=50 mg/dLLowS
1917-04-27Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS
1917-04-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS

Physical Exam

Vital signs recorded on 1917-04-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 136/86, pulse 76; weight 77.2 kg
CardiovascularRegular rhythm; no ankle swelling
AbdomenSoft, non-tender

Problems

ProblemClinical statusVerificationCodeProvenance
Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirmresolvedconfirmed R03.0S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks.
Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 1912 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigatedresolvedconfirmed R80.9S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks.
Hypertension, stage 2, confirmed by 24-hour ambulatory monitoring (24-hour mean 149/94, daytime 154/98, night 140/88 without the normal nighttime fall), with left ventricular hypertrophy on ECG and mild hypertensive retinopathy; synthetic modern episode linked to her documented high blood pressureactiveconfirmed I12.9S — Synthetic modern diagnosis anchored to the documented hypertension and nephritis.
Chronic kidney disease G3a A2 (eGFR 54 to 55 mL/min/1.73 m2 by the race-free CKD-EPI 1912 equation; albumin-to-creatinine ratio 286 to 294 mg/g; present for more than three months), most likely hypertensive kidney disease; bland urine sediment and normal-sized kidneys on ultrasound; 5-year kidney failure risk 1.6%activeconfirmed N18.31S — Synthetic kidney findings anchored to the documented nephritis and death from kidney disease.
Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate)activeconfirmed E78.5S — Synthetic laboratory finding.
Viral gastroenteritis after a sales convention, with mild volume depletion and losartan and empagliflozin held under her sick-day rules; no acute kidney injury; resolvedresolvedconfirmed A08.4S — Synthetic intercurrent illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationOffice blood pressure (seated, five minutes' rest, validated device, correct cuff, average of two readings)Every visitCompleted today136/86
Self-managementHome blood pressure readingsTwo readings morning and evening for seven days to confirm and after each change; then twice a week, travel days includedCompleted todayAverage 134/84
ExaminationWeight and BMIEvery visitCompleted today77.2 kg
LaboratoryPotassium, bicarbonate, creatinine and eGFR (CKD-EPI 1912, race-free)Two to four weeks after starting or increasing losartan or empagliflozin; then every six monthsDeferredMissed: the panel due two to four weeks after the losartan increase was not done because she was on a three-week tour with no laboratory day booked, and the panel planned a week after the gastroenteritis was missed for another trip. No harm judging by the sick-visit panel (potassium 4.9 mmol/L, creatinine 1.46 mg/dL while volume depleted) and today's results (potassium 4.7 mmol/L, bicarbonate 24 mmol/L, creatinine 1.31 mg/dL, eGFR 50). Corrective action: her office books each laboratory check on a home day before trips are scheduled (INT-012)
LaboratoryUrine albumin-to-creatinine ratioRepeat to confirm; about three months after a treatment change; then every six months for G3a A2Completed today176 mg/g, 39% lower
LaboratoryLipid panel and ALT4 to 12 weeks after starting a statin, then yearlyCompleted todayLDL 98, total cholesterol 172, HDL 48, triglycerides 130 mg/dL; ALT 22 U/L
Medication safetyMedicine safety and reconciliation: no NSAIDs, sick-day rules, dizziness, ankle swelling, genital infection, cough, adherence across time zonesEvery visitCompleted todaySick-day rules applied correctly during the gastroenteritis; no side effects; amlodipine added
Self-managementSodium and diet counselingEvery visitCompleted todaySauces on the side and no added salt at banquets; water on travel days

Goal progress:

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026)

Follow-up: Preventive visit in about six weeks. Six-month review in the summer with urine albumin, kidney function and hemoglobin, booked on a home day. Call for ankle swelling, dizziness, or vomiting or diarrhea (hold losartan and empagliflozin). Next scheduled visit 1917-06-08: periodic adult preventive visit. [S]